----
Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines: revenue of $200.6M vs. $194.6M expected, and GAAP EPS of $0.01 vs. a $(0.26) loss expected. Despite a 7.6% YoY revenue decline due to U.S. reimbursement headwinds, gross margin expanded to 85.5%, meeting expectations. The company significantly raised its FY26 revenue guidance to $835M-$875M and announced 'Project Horizon' to redeploy $30M toward growth initiatives.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Inspire Medical(INSP) the Revenue is 200.58 M (-7.6%), Beat estimate;the EBIT is 3.183 M (+196%), Beat estimate;the EPS is 0.01 (+108.3%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.20B7.60%
0.19B10.35%
+0.01B2.75%
EBITExceed expectations
0.00B195.99%
-0.01B300.70%
+0.02B496.69%
EPSExceed expectations
0.01108.33%
-0.2582115.16%
+0.2682223.49%
Upcoming earnings report - Q3 FY2026
Available dateNov 2, 2026
Estimate Revenue$204.32 M
Estimate EBIT$1.016 M
Estimate EPS-$0.3125
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf
